Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Arantzazu Barquín-García"'
Autor:
Juan José Serrano Domingo, Teresa Alonso Gordoa, Javier Lorca Álvaro, Javier Molina-Cerrillo, Arantzazu Barquín García, Olga Martínez Sáez, Javier Burgos Revilla, Alfredo Carrato, Sara Álvarez Rodríguez
Publikováno v:
Therapeutic Advances in Urology, Vol 13 (2021)
Introduction: Androgenic deprivation therapies have been linked to the development of metabolic syndrome (MS) and cardiovascular diseases, which may lead to a poorer survival in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC). W
Externí odkaz:
https://doaj.org/article/bd7dd74fc3904ca98d86d7a190c3ecec
Autor:
Elena Sevillano Fernández, Rodrigo Madurga de Lacalle, Juan Francisco Rodriguez Moreno, Arantzazu Barquín García, Mónica Yagüe Fernández, Paloma Navarro Alcaraz, María Barba Llacer, Miguel Quiralte Pulido, Jesús García-Donás Jiménez
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 15, p 4483 (2022)
Fibroblast growth factor receptor (FGFR) genomic alterations (GAs) represent an actionable target, key to the pathogenesis of some urothelial cancers (UCs). Though FGFR GAs are common in noninvasive UC, little is known about their role in the metasta
Externí odkaz:
https://doaj.org/article/dc11412cdbff443c821cf74bda6ffce2
Autor:
Martin Köbel, Eun‐Young Kang, Ashley Weir, Peter F Rambau, Cheng‐Han Lee, Gregg S Nelson, Prafull Ghatage, Nicola S Meagher, Marjorie J Riggan, Jennifer Alsop, Michael S Anglesio, Matthias W Beckmann, Christiani Bisinotto, Michelle Boisen, Jessica Boros, Alison H Brand, Angela Brooks‐Wilson, Michael E Carney, Penny Coulson, Madeleine Courtney‐Brooks, Kara L Cushing‐Haugen, Cezary Cybulski, Suha Deen, Mona A El‐Bahrawy, Esther Elishaev, Ramona Erber, Sian Fereday, AOCS Group, Anna Fischer, Simon A Gayther, Arantzazu Barquin‐Garcia, Aleksandra Gentry‐Maharaj, C Blake Gilks, Helena Gronwald, Marcel Grube, Paul R Harnett, Holly R Harris, Andreas D Hartkopf, Arndt Hartmann, Alexander Hein, Joy Hendley, Brenda Y Hernandez, Yajue Huang, Anna Jakubowska, Mercedes Jimenez‐Linan, Michael E Jones, Catherine J Kennedy, Tomasz Kluz, Jennifer M Koziak, Jaime Lesnock, Jenny Lester, Jan Lubiński, Teri A Longacre, Maria Lycke, Constantina Mateoiu, Bryan M McCauley, Valerie McGuire, Britta Ney, Alexander Olawaiye, Sandra Orsulic, Ana Osorio, Luis Paz‐Ares, Teresa Ramón y Cajal, Joseph H Rothstein, Matthias Ruebner, Minouk J Schoemaker, Mitul Shah, Raghwa Sharma, Mark E Sherman, Yurii B Shvetsov, Naveena Singh, Helen Steed, Sarah J Storr, Aline Talhouk, Nadia Traficante, Chen Wang, Alice S Whittemore, Martin Widschwendter, Lynne R Wilkens, Stacey J Winham, Javier Benitez, Andrew Berchuck, David D Bowtell, Francisco J Candido dos Reis, Ian Campbell, Linda S Cook, Anna DeFazio, Jennifer A Doherty, Peter A Fasching, Renée T Fortner, María J García, Marc T Goodman, Ellen L Goode, Jacek Gronwald, David G Huntsman, Beth Y Karlan, Linda E Kelemen, Stefan Kommoss, Nhu D Le, Stewart G Martin, Usha Menon, Francesmary Modugno, Paul DP Pharoah, Joellen M Schildkraut, Weiva Sieh, Annette Staebler, Karin Sundfeldt, Anthony J Swerdlow, Susan J Ramus, James D Brenton
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 9, Iss 3, Pp 208-222 (2023)
Abstract Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high‐grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carc
Externí odkaz:
https://doaj.org/article/493c5874781345c8971b7e798d52a02b
Autor:
Arantzazu Barquín-García, Elena Fernández-Sevillano, Paloma Navarro, Cristina Rodríguez-Antona, Monica Yague-Fernandez, Juan María Roldan-Romero, Juan Francisco Rodriguez-Moreno, Sergio Ruiz-Llorente, Raquel Martín, Sandra Amarilla-Quintana, Jesús García-Donas
Publikováno v:
Cancer Research. 80:5288-5288
Introduction The Fibroblast Growth Factor Receptor (FGFR) has become a key target in urothelial cancer. The FGFR inhibitor (FGFRi) erdafitinib has been approved for clinical use and many others are in development. Unfortunately, responses have shown